CNSY — CERENOME, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1095981 ·
Last close
$0.63
Market Cap
$4.78M
52W High
$19.00
52W Low
$0.43
ADV30
1,540,592
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -9,057,000 | -9,006,000 | 14,030,000 | 2,366,000 | 8,567,000 |
| Mar 2026 | 0 | — | -7,119,000 | -6,946,000 | 19,916,000 | 3,022,000 | 7,955,000 |
| Dec 2025 | 0 | — | -5,742,000 | -5,713,000 | 16,325,000 | 4,256,000 | 12,329,000 |
| Sep 2025 | 0 | — | -4,482,000 | -4,423,000 | 18,670,000 | 13,289,000 | 13,616,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,175,000
Investing CF
$-2,947,000
Financing CF
$25,255,000
CapEx
$-1,374,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-2.74
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-531,817,000
Inventory
—
Receivables
$1,969,000
ST Investments
$6,221,000
EBIT TTM
$-23,005,000
Pretax Income TTM
$-26,088,000
Interest Exp TTM
$3,083,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,203,000
EBITDA
$-25,945,000
Free Cash Flow
$-13,969,750
Enterprise Value
$-1,331,338
Total Cash
$8,587,000
Total Debt
$44,000
Shares Out
7,589,625
Trailing EPS
$-3.36
Book Value
$0.75
ROE
-614.1%
ROA
-135.4%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -15,298,000 | -22,386,000 | 16,325,000 | 12,329,000 | 3,996,000 | -20,775,000 |
| Dec 2024 | 0 | -14,695,000 | -12,978,000 | 6,633,000 | 15,582,000 | -8,949,000 | -10,554,000 |
| Dec 2023 | 0 | -13,321,000 | -13,316,000 | 11,388,000 | 12,736,000 | -1,348,000 | -12,851,000 |
| Dec 2022 | 0 | -19,712,000 | -20,275,000 | 23,867,000 | 17,422,000 | 6,445,000 | -12,972,000 |
TTM Snapshot
Revenues TTM
$4,203,000
NetIncome TTM
$-26,088,000
OpCashFlow TTM
—
Assets (Latest)
$14,030,000
Forward EPS
$-2.48
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PCSA | Processa Pharmaceuticals, Inc. | $4.84M | $1.73 | — |
| LTRN | Lantern Pharma Inc. | $4.67M | $0.37 | — |
| CDT | CDT Equity Inc. | $4.93M | $0.36 | — |
| PULM | Pulmatrix, Inc. | $5.00M | $1.37 | — |
| CMND | Clearmind Medicine Inc. | $5.13M | $3.45 | — |
News headlines (Yahoo Finance, 1h cache)
Cerenome (CNSY) Q3 2026 Earnings Call Transcript
2026-11-16 20:43 · Yahoo
Cerenome Reports Interim REYOBIQ Repeat-Dosing Data in Leptomeningeal Metastases Study
2026-11-16 13:36 · Yahoo
Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting
2026-11-16 12:30 · Yahoo
Cerenome (CNSY) Reports Q3 Loss, Beats Revenue Estimates
2026-11-13 22:25 · Yahoo
Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress
2026-11-13 22:19 · Yahoo
Cerenome: Q3 Earnings Snapshot
2026-11-13 22:13 · Yahoo
Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16
2026-11-12 12:30 · Yahoo
Cerenome Appoints Director Ron Andrews as Chief Business Officer
2026-11-10 12:30 · Yahoo
Cerenome Secures National In-Network Agreement with Aetna for CNSide®
2026-11-04 12:30 · Yahoo
Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma
2026-10-29 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.